- Conditions
- Acute Uncomplicated Appendicitis
- Interventions
- 1 gm IV ertapenem at enrollment, 1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days, Appendectomy
- Drug · Procedure
- Lead sponsor
- Olive View-UCLA Education & Research Institute
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Sylmar, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–23
of 23
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy
- Interventions
- Taste Test
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy
- Interventions
- cefdinir (Omnicef), amoxicillin
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 4 Years to 8 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Acute Otitis Media
- Interventions
- cefdinir
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 6 Months to 4 Years
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Clovis, California • Dinuba, California + 9 more
- Conditions
- Healthy
- Interventions
- Cefdinir for oral suspension 250 mg/5mL, OMNICEF® for oral suspension 250 mg/5mL
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Antibiotics, Pituitary Adenoma
- Interventions
- Placebo, Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
- Drug
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Urinary Tract Infection
- Interventions
- Cefixime, Cephalexin, Placebo, Trimethoprim/Sulfamethoxazole
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Months to 10 Years
- Enrollment
- 717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Urinary Tract Infections
- Interventions
- Gentamicin, Standard of Care
- Drug
- Lead sponsor
- Mercy Health Ohio
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Youngstown, Ohio
- Conditions
- Pneumonia
- Interventions
- Amoxicillin, Amoxicillin-clavulanate, Cefdinir, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 71 Months
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Louisville, Kentucky + 6 more
- Conditions
- Healthy
- Interventions
- Cefdinir for oral suspension 250 mg/5mL, OMNICEF® for oral suspension 250 mg/5mL
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Healthy
- Interventions
- cefdinir (Omnicef), amoxicillin
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 4 Years to 8 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2003
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • St. Petersburg, Florida • Miamiville, Ohio
- Conditions
- Acute Otitis Media
- Interventions
- cefdinir (Omnicef), amoxicillin
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 6 Months to 6 Years
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Ozark, Alabama + 28 more
- Conditions
- Acute Otitis Media, Acute Sinusitis, Group A Streptococcal Pharyngitis
- Interventions
- Broad-spectrum antibiotics, Narrow-spectrum antibiotics
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 6 Months to 12 Years
- Enrollment
- 2,472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Bacterial Sinusitis
- Interventions
- Cefdinir (drug), amoxicillin/clavulanate
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy
- Interventions
- Cefdinir Capsules 300 mg, OMNICEF® Capsule 300 mg
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 2
- States / cities
- East Grand Forks, Minnesota • Fargo, North Dakota
- Conditions
- Healthy
- Interventions
- Cefdinir Capsules 300 mg, OMNICEF® 300 mg
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 2
- States / cities
- East Grand Forks, Minnesota • Fargo, North Dakota
- Conditions
- Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
- Interventions
- Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more
- Conditions
- Acute Otitis Media
- Interventions
- cefdinir (Omnicef), azithromycin
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 6 Months to 6 Years
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 30
- States / cities
- Columbiana, Alabama • Montgomery, Alabama • Ozark, Alabama + 24 more
- Conditions
- Osteomyelitis
- Interventions
- oral antibiotics, intravenous antibiotics
- Drug · Procedure
- Lead sponsor
- Julio Ramirez
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Healthy
- Interventions
- cefdinir (Omnicef), azithromycin
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 4 Years to 8 Years
- Enrollment
- 157 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2003
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • St. Petersburg, Florida • Miamiville, Ohio
- Conditions
- Snoring, Strep Throat
- Interventions
- Antibiotic
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Acute Bacterial Sinusitis
- Interventions
- cefdinir (Omnicef), levofloxacin
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Eclectic, Alabama + 16 more